Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2007 1
2009 2
2011 1
2012 1
2014 4
2015 8
2016 4
2017 1
2018 1
2020 4
2021 11
2022 8
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Pabst T, Vey N, Adès L, Bacher U, Bargetzi M, Fung S, Gaidano G, Gandini D, Hultberg A, Johnson A, Ma X, Müller R, Nottage K, Papayannidis C, Recher C, Riether C, Shah P, Tryon J, Xiu L, Ochsenbein AF. Pabst T, et al. Among authors: xiu l. Haematologica. 2023 Jul 1;108(7):1793-1802. doi: 10.3324/haematol.2022.281563. Haematologica. 2023. PMID: 36779592 Free PMC article. Clinical Trial.
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Pabst T, Papayannidis C, Demirkan F, Doronin V, Fogliatto LM, Guttke C, Gyan E, Hamad N, Herrera P, Hultberg A, Jacobs J, Johnson AJ, Langlois A, Ma X, Martinelli G, Arnan M, Müller R, Nottage K, Ofran Y, Özcan M, Samoilova O, Tolbert JA, Trudel GC, Xiu L, Vey N, Wei AH. Pabst T, et al. Among authors: xiu l. Lancet Haematol. 2023 Nov;10(11):e902-e912. doi: 10.1016/S2352-3026(23)00207-7. Lancet Haematol. 2023. PMID: 37914483 Clinical Trial.
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes.
Garcia-Manero G, Diez-Campelo M, Vellenga E, Jacoby MA, Merchan B, Breems D, Cortelezzi A, Doronin V, Gomez V, Beckers M, Della Porta MG, Varsos H, Xiu L, DeAngelis N, Nnane I, Rose E, van Eygen K. Garcia-Manero G, et al. Among authors: xiu l. Am J Hematol. 2021 Apr 1;96(4):E111-E114. doi: 10.1002/ajh.26095. Epub 2021 Jan 31. Am J Hematol. 2021. PMID: 33448430 Free article. Clinical Trial. No abstract available.
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh SP, Ozcan MA, Knapper S, Cortes J, Pollyea DA, Ossenkoppele G, Giralt S, Döhner H, Heuser M, Xiu L, Singh I, Huang F, Larsen JS, Wei AH. Montesinos P, et al. Among authors: xiu l. Leukemia. 2021 Jan;35(1):62-74. doi: 10.1038/s41375-020-0773-5. Epub 2020 Mar 16. Leukemia. 2021. PMID: 32203138 Free PMC article. Clinical Trial.
49 results